FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk — FDA Drug Information Updates — Overcast

Overcast Podcaster Info Ads Log In

FDA Drug Information Updates

FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk

January 4, 2018

0:00 -:--

Speed

–1×+++++2×+

Website • Share link • Share link with timestamp